口腔医学研究

口腔医学研究 ›› 2017, Vol. 33 ›› Issue (12): 1298-1301.DOI: 10.13701/j.cnki.kqyxyj.2017.12.015

• 临床研究论著 • 上一篇    下一篇

口腔鳞癌新辅助化疗前后多药耐药相关蛋白的表达及临床疗效分析

邬利波,潘淑婷,邱嘉旋*   

  1. 南昌大学第一附属医院口腔颌面外科 江西 南昌 330006
  • 收稿日期:2017-01-15 出版日期:2017-12-20 发布日期:2018-01-03
  • 通讯作者: 邱嘉旋,E-mail:qiujiaxuan@163.com
  • 作者简介:邬利波(1984~ ),女,江西萍乡人,硕士,主治医师,口腔颌面外科。
  • 基金资助:
    江西省科技厅自然科学基金重大项目(编号:20152ACB20019)

Expression Level and Clinical Efficacy of Multidrug Resistant Proteins before and after Neoadjuvant Chemotherapy in OSCC.

WU Li-bo, PAN Shu-ting, QIU Jia-xuan*.   

  1. Department of Oral＆Maxillofacial Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
  • Received:2017-01-15 Online:2017-12-20 Published:2018-01-03

PDF (PC)

234

摘要： 目的: 观察口腔鳞癌患者新辅助化疗疗效与5年生存率的关系,并探讨P-gp、MRP1、GST-π与新辅助化疗疗效的关系。方法: 1)收集南昌大学第一附属医院诊治的口腔鳞癌石蜡标本77例(有效组50例,无效组27例),随访5年生存时间,Envision法检测P-gp、MRP1、GST-π表达水平;2)收集本单位口腔鳞癌新鲜标本33例(有效组18例,无效组15例),qPCR、WesternBlot法检测P-gp、MRP1、GST-π表达水平。结果: 1)Kaplan-Meier显示:有效组5年生存率高于无效组(P<0.05)。2)Envision、qPCR 、WesternBlot显示:无效组化疗后P -gp、MRP1表达上升量较有效组有显著差异(P<0.05),而GST-π表达上升量无显著差异(P>0.05)。结论: 口腔鳞癌新辅助化疗有效组5年生存率明显高于无效组;化疗疗效与P-gp、MRP1表达相关,表达上升量越高,疗效越差。

关键词: 口腔鳞癌, 新辅助化疗, 多药耐药相关蛋白, 5年生存率

Abstract: Objective: To observe the relationship between therapeutic efficacy and 5-year survival rate of OSCC patients after neoadjuvant chemotherapy, and to explore the relationship between P-gp, MRP1, or GST-π and therapeutic efficacy after neoadjuvant chemotherapy. Methods: Seventy-seven OSCC paraffin specimens (50 valids and 27 invalids) were collected from the First Affiliated Hospital of Nanchang University. The 5-year survival time was followed up. Envision assay was used to determine the expression level of P-gp, MRP1, and GST-π. Thirty-three OSCC fresh specimens (18 valids and 15 invalids) were collected. qPCR and Western Blot assay were used to detect the expression level of P-gp, MRP1, and GST-π. Results: The Kaplan-Meier assay showed that 5-year survival rate of valid group was better than that of invalid group (P<0.05). The results of Envision, qPCR, and Western Blot showed that the increased expression levels of P-gp and MRP1 in valid group were significantly higher than those in invalid group (P<0.05). Conclusion: The 5-year survival rate of valid group was obviously higher than that of invalid group after the neoadjuvant chemotherapy. The expression levels of P-gp and MRP1 were related to therapeutic efficacy. The higher expression levels of P-gp and MRP1 were followed by the inferior therapeutic efficacy.

Key words: OSCC Neoadjuvant chemotherapy , Multidrug Resistant related proteins , 5-year survival rate

中图分类号: